Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 19,49
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
Librería: GreatBookPrices, Columbia, MD, Estados Unidos de America
EUR 28,93
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
EUR 29,14
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New. In.
EUR 25,80
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: As New. Unread book in perfect condition.
EUR 28,41
Cantidad disponible: Más de 20 disponibles
Añadir al carritoCondición: New.
EUR 34,50
Cantidad disponible: Más de 20 disponibles
Añadir al carritoGebunden. Condición: New. Klappentextrnrn This remarkably insightful book gives true meaning to the apocryphal moan from the pharmaceutical CEO as he traveled home after an FDA slap down: Drug development ain t for sissies . Peter Kowey, MD, author of LETHAL RHYTHM, DE.
Idioma: Inglés
Publicado por Author Solutions Inc Jun 2016, 2016
ISBN 10: 1491797630 ISBN 13: 9781491797631
Librería: AHA-BUCH GmbH, Einbeck, Alemania
EUR 28,42
Cantidad disponible: 1 disponibles
Añadir al carritoBuch. Condición: Neu. Neuware - 'This remarkably insightful book gives true meaning to the apocryphal moan from the pharmaceutical CEO as he traveled home after an FDA slap down: 'Drug development ain't for sissies'.' Peter Kowey, MD, author of LETHAL RHYTHM, DEADLY RHYTHM and THE EMPTY NETWhen Roger Mills, a medical school professor, made a late-career move from academic cardiology to the pharmaceutical industry, he had no idea what the next decade would bring. At the University of Florida in the late 1990s, he had been a clinical investigator in a phase 2 trial studying the dosing and efficacy of nesiritide, which Scios Inc. was attempting to bring to the market. He joined the company in 2005, and soon became its vice president for medical affairs.Nesiritide was the biotechnology company's only product in clinical development, and after a stunning turn of events at a Food and Drug Administration meeting in 1999, company president Dick Brewer had to use all his smarts to keep the company together and reverse its fortunes.</pJohnson & Johnson would eventually acquire the company in 2003 for $2.4 billion, but then found it would have to decide how to deal with safety concerns raised about the drug after two scientific publications claimed it could cause kidney failure and death.Get a revealing look at what it really takes to develop and introduce a drug to market and all the things that can go wrong in Nesiritide.
Librería: PBShop.store US, Wood Dale, IL, Estados Unidos de America
EUR 31,08
Cantidad disponible: Más de 20 disponibles
Añadir al carritoHRD. Condición: New. New Book. Shipped from UK. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Librería: PBShop.store UK, Fairford, GLOS, Reino Unido
EUR 29,20
Cantidad disponible: Más de 20 disponibles
Añadir al carritoHRD. Condición: New. New Book. Delivered from our UK warehouse in 4 to 14 business days. THIS BOOK IS PRINTED ON DEMAND. Established seller since 2000.
Librería: THE SAINT BOOKSTORE, Southport, Reino Unido
EUR 28,42
Cantidad disponible: Más de 20 disponibles
Añadir al carritoHardback. Condición: New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days.